Key points from article :
Iambic Therapeutics, a biotechnology company specializing in AI-driven drug discovery, has secured an additional $50 million in funding, bringing its total Series B financing to $150 million. The investment, backed by new and existing investors, will support the advancement of Iambic’s pipeline of cancer treatments, including a brain-penetrant HER2 inhibitor and a novel dual CDK2/4 inhibitor aimed at overcoming drug resistance in solid tumours.
The company leverages cutting-edge AI models combined with automated high-throughput experiments to rapidly design and test new drug candidates. By integrating physics-based principles and machine learning, Iambic's platform accelerates drug discovery, enabling weekly iterations in the search for effective treatments. Investors recognize Iambic as a leader in AI-powered drug development, with the potential to bring life-saving medicines to patients faster than traditional methods.
Founded in 2019 and based in San Diego, Iambic Therapeutics is pioneering a new era of AI-driven medicine. Its innovative approach has already delivered promising clinical-stage drug candidates, reinforcing its position at the forefront of modern oncology drug discovery.
